Effects of combined treatment with CD25- and CD154-specific monoclonal antibodies in non-human primate allotransplantation.
Effects of combined treatment with CD25- and CD154-specific monoclonal antibodies in non-human primate allotransplantation.
复制标题
CD25 和 CD154 特异性单克隆抗体联合治疗在非人灵长类同种异体移植中的效果。
DOI：
10.1046/j.1600-6135.2003.00235.x
复制
发表时间：
2003
期刊：
影响因子：
--
通讯作者：
Kirk,AllanD
中科院分区：
文献类型：
--
作者：
Xu,He;Elster,EricA;Blair,PatrickJ;Burkly,LindaC;Tadaki,DouglasK;Harlan,DavidM;Kirk,AllanD
The CD154‐specific monoclonal antibody (Mab) hu5c8 greatly prolongs allograft survival in primates. The CD25‐specific Mab daclizumab has not, to date, been paired with hu5c8. We evaluated the effects of hu5c8in vitro, alone and in combination with daclizumab on rhesus‐mixed lymphocyte reactions (MLRs). We then evaluated therapy with hu5c8 and daclizumab in four monkey renal allograft recipients compared with monkeys untreated or contemporaneously treated with hu5c8 alone. Lymphocyte proliferation in MLR was reduced by both daclizumab and hu5c8, and their combined effects were additive. Rejection‐free allograft survival in monkeys treated with both hu5c8 and daclizumab (74–479 days) was not significantly better than animals treated with hu5c8 alone (257–587 days), and one combined therapy animal rejected while still on hu5c8 therapy, a condition not typically seen with hu5c8 monotherapy. Although daclizumab and hu5c8 are additively effective in MLR, they do not appear to be synergisticin vivoin rhesus monkeys.
